Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Wegovy notice their appetite dropping within the first one to four weeks, though meaningful weight loss on the scales typically becomes visible after six to twelve weeks of treatment. The timeline depends on which dose you're on, how your body responds, and the lifestyle changes you make alongside it. Wegovy (semaglutide) is a prescription-only medicine; a GPhC-registered prescriber assesses whether it's right for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The earliest sign that Wegovy is doing something is usually a shift in appetite, not a number on the scales. Semaglutide works by activating GLP-1 receptors involved in hunger signalling and gastric emptying, and that effect can begin within the first few days of a 0.25mg starting dose. Meals start to feel like enough sooner. Snacking urges settle. Some people notice this within a week; for others it takes closer to four weeks.
What you won't see immediately is dramatic weight loss, and that's by design. The dose escalation schedule (0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, before reaching the 2.4mg maintenance dose) exists to let your digestive system adjust gradually. Each step takes roughly four weeks. That means the dose doing the heaviest lifting therapeutically typically isn't reached until around week sixteen or beyond.
Practically, that phase covers a lot of ordinary life: a month that includes payday, a bank holiday, a week when you're travelling. Weight loss during these earlier weeks is modest but adds up. Our clinical team at nume's prescribing lead describes this as the period where people build confidence in the medicine, not the phase where dramatic results land.
The NHS patient information for semaglutide confirms that your prescriber will typically review whether the medicine is working for you at the six-month point, that's the clinical benchmark, not week one.
Weight loss tends to pick up once you're at or approaching the maintenance dose. In the STEP 1 clinical trial (68 weeks, 1,961 adults with obesity or overweight and at least one weight-related condition) participants lost an average of around 15% of their body weight at the 2.4mg dose alongside lifestyle changes. The losses weren't front-loaded; meaningful reductions continued right through the trial period, with the rate generally steepening as the dose increased.
By around week twelve, most people on a standard titration schedule will have lost some visible weight, typically in the range of two to five percent of starting body weight, though there's real individual variation here. If you're curious about how soon you will see results from Wegovy, the timeline depends on where you are in the dose schedule. By months four to six, at or near full dose, that figure tends to be higher. The trial published in the New England Journal of Medicine gives the clearest picture of what population-level outcomes look like over time, though individual responses differ substantially.
One honest note: some people are slower starters. Genetics, starting weight, baseline activity, dietary habits and how consistently the injections are taken all influence the pace. If you're wondering whether your results are normal, that's exactly the kind of question to raise with your prescriber, not one to answer by comparing yourself to online forums.
For context on how Wegovy's results compare to those of tirzepatide (Mounjaro), the weight-loss treatments overview at nume walks through what the head-to-head evidence shows.
It may, for some people. The MHRA approved a higher 7.2mg maintenance dose of Wegovy in January 2026, and then approved a dedicated single-dose 7.2mg pen in April 2026, making the UK the first to have that option in a single weekly injection. Trials at the higher dose reported average weight loss of around 20.7% over 72 weeks, which narrows the gap with tirzepatide at higher doses considerably.
This matters for the results timeline because the starting point and titration remain the same: 0.25mg, worked up gradually by your prescriber. Understanding how long it takes to see results from Wegovy is especially relevant here, since the 7.2mg maintenance dose simply represents a higher ceiling of potential weight loss for those who need it and tolerate it well. Not everyone will require or reach that dose; your prescriber's assessment guides whether it's appropriate.
If you'd like to read more about the treatment itself before deciding anything, the Wegovy overview page covers how it works, who it's licensed for, and what the full dose journey looks like. The Wegovy results page goes deeper into the clinical evidence for different weight-loss outcomes.
The clinical trials are a population average, your experience sits somewhere on a distribution around that. Several factors influence where. Body weight at the start matters: people with higher starting weights often lose more in absolute terms, though percentage losses vary. Dietary changes alongside the medicine make a meaningful difference. Wegovy isn't designed to replace a reduced-calorie approach; it makes one much easier to sustain by reducing appetite.
Consistency counts too. Missing injections or delaying dose increases (outside of tolerability reasons) slows progress. Many people find it helpful to read about how soon you see results with Wegovy so they know what to expect during the early weeks, particularly when GI side effects such as nausea, constipation, and indigestion can affect appetite in ways that are separate from the medicine's intended effect; eating enough protein and staying hydrated matters more than people expect.
Sleep, stress and activity level all contribute, as they do with any weight-management approach. NHS guidance on healthy weight covers the lifestyle factors that work alongside medication.
If you're weighing up cost alongside how quickly results come and how long treatment typically runs, the Wegovy price comparison page puts private UK treatment costs in context. And if you want to understand the full range of what's available, the weight-loss treatments page is a good starting point.
When you're ready, a free consultation with our prescribers is the first step. Your answers are reviewed the same day by a real clinician, your file lands on a prescriber's desk, not in a queue for automated processing. Start your free consultation and get a clinical view on whether Wegovy is suitable for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.